Cronos Group (CRON.TO) Stock Price

Cronos Group Price

TSX·CLOSED
2.74USD+0.06 (+2.06 %)
Market closed

Revenue has compounded at 91.7% per year over the past 9 years to 146.59 M USD. Earnings per share have grown at 44.5% per year over the last 9 years. Cronos Group's net margin stands at -6.4%, up from -532.2% several years earlier. Analysts set a median price target of 3.37 USD, implying 22.9% above the current price. Of 8 analysts, 7 rate the stock a buy — an overall Buy consensus. The stock trades about 33% above its 52-week low.

Cronos Group stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Cronos Group over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Cronos Group stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Cronos Group's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Cronos Group Stock Price History
DateCronos Group Price
6/19/20262.74 USD
6/18/20262.68 USD
6/17/20262.70 USD
6/16/20262.60 USD
6/15/20262.65 USD
6/12/20262.71 USD
6/11/20262.75 USD
6/10/20262.83 USD
6/9/20262.82 USD
6/8/20262.80 USD
6/5/20262.79 USD
6/4/20262.81 USD
6/3/20262.72 USD
6/2/20262.74 USD
6/1/20262.86 USD
5/29/20262.84 USD
5/28/20262.86 USD
5/27/20262.74 USD
5/26/20262.75 USD
5/25/20262.77 USD
5/22/20262.73 USD
5/21/20262.72 USD
5/20/20262.66 USD
5/19/20262.61 USD
5/15/20262.64 USD
5/14/20262.74 USD
5/13/20262.73 USD
5/12/20262.77 USD
5/11/20262.74 USD
5/8/20262.53 USD
5/7/20262.57 USD
5/6/20262.63 USD
5/5/20262.63 USD
5/4/20262.65 USD
5/1/20262.64 USD
4/30/20262.64 USD
4/29/20262.57 USD
4/28/20262.64 USD
4/27/20262.69 USD
4/24/20262.66 USD
4/23/20262.58 USD
4/22/20262.80 USD
4/21/20262.74 USD
4/20/20262.76 USD
4/17/20262.70 USD
4/16/20262.69 USD
4/15/20262.74 USD
4/14/20262.59 USD
4/13/20262.61 USD
4/10/20262.61 USD
4/9/20262.58 USD
4/8/20262.58 USD
4/7/20262.56 USD
4/6/20262.58 USD
4/2/20262.53 USD
3/27/20262.54 USD
3/26/20262.56 USD
3/25/20262.65 USD
3/24/20262.57 USD
3/23/20262.52 USD
3/20/20262.41 USD
3/19/20262.47 USD
3/18/20262.46 USD
3/17/20262.59 USD
3/16/20262.56 USD
3/13/20262.51 USD
3/12/20262.49 USD
3/11/20262.56 USD
3/10/20262.53 USD
3/9/20262.53 USD
3/6/20262.56 USD
3/5/20262.58 USD
2/26/20262.68 USD
2/25/20262.77 USD
2/24/20262.73 USD
2/23/20262.64 USD
2/20/20262.68 USD
2/19/20262.72 USD
2/18/20262.67 USD
2/17/20262.67 USD
2/13/20262.61 USD
2/12/20262.59 USD
2/11/20262.62 USD
2/10/20262.67 USD
2/9/20262.62 USD
2/6/20262.63 USD
2/5/20262.58 USD
2/4/20262.58 USD
2/3/20262.59 USD
2/2/20262.47 USD
1/30/20262.50 USD
1/29/20262.56 USD
1/28/20262.69 USD
1/27/20262.73 USD
1/26/20262.70 USD
1/23/20262.77 USD
1/22/20262.71 USD
1/21/20262.60 USD
1/20/20262.56 USD
1/19/20262.54 USD
1/16/20262.54 USD
1/15/20262.61 USD
1/14/20262.64 USD
1/13/20262.70 USD
1/12/20262.73 USD
1/9/20262.68 USD
1/8/20262.65 USD
1/7/20262.69 USD
1/6/20262.68 USD
1/5/20262.70 USD
1/2/20262.69 USD
12/31/20252.63 USD
12/30/20252.66 USD
12/29/20252.66 USD
12/24/20252.72 USD
12/23/20252.73 USD
12/22/20252.78 USD
12/19/20252.96 USD
12/18/20253.00 USD
12/17/20253.09 USD
12/16/20253.20 USD
12/15/20253.04 USD
12/12/20253.26 USD
12/11/20252.84 USD
12/10/20252.82 USD
12/9/20252.67 USD
12/8/20252.48 USD
12/5/20252.50 USD
12/4/20252.51 USD
12/3/20252.50 USD
12/2/20252.45 USD
12/1/20252.50 USD
11/28/20252.46 USD
11/27/20252.48 USD
11/26/20252.48 USD
11/25/20252.45 USD
11/24/20252.45 USD
11/21/20252.38 USD
11/20/20252.31 USD
11/19/20252.40 USD
11/18/20252.44 USD
11/17/20252.42 USD
11/14/20252.46 USD
11/13/20252.50 USD
11/12/20252.54 USD
11/11/20252.50 USD
11/10/20252.55 USD
11/7/20252.46 USD
11/6/20252.46 USD
11/5/20252.46 USD
11/4/20252.46 USD
11/3/20252.53 USD
10/31/20252.52 USD
10/30/20252.44 USD
10/29/20252.46 USD
10/28/20252.50 USD
10/27/20252.48 USD
10/24/20252.53 USD
10/23/20252.47 USD
10/22/20252.40 USD
10/21/20252.50 USD
10/20/20252.53 USD
10/17/20252.50 USD
10/16/20252.47 USD
10/15/20252.58 USD
10/14/20252.54 USD
10/10/20252.51 USD
10/9/20252.72 USD
10/8/20252.68 USD
10/7/20252.60 USD
10/6/20252.55 USD
10/3/20252.59 USD
10/2/20252.59 USD
10/1/20252.66 USD
9/30/20252.78 USD
9/28/20252.97 USD
9/25/20252.62 USD
9/24/20252.63 USD
9/23/20252.63 USD
9/22/20252.58 USD
9/19/20252.61 USD
9/18/20252.68 USD
9/17/20252.57 USD
9/16/20252.59 USD
9/15/20252.54 USD
9/12/20252.52 USD
9/11/20252.59 USD
9/10/20252.54 USD
9/9/20252.56 USD
9/8/20252.49 USD
9/5/20252.52 USD
9/4/20252.50 USD
9/3/20252.52 USD
9/2/20252.53 USD
8/29/20252.60 USD
8/28/20252.60 USD
8/27/20252.57 USD
8/26/20252.55 USD
8/25/20252.61 USD
8/22/20252.61 USD
8/21/20252.56 USD
8/20/20252.42 USD
8/19/20252.48 USD
8/18/20252.54 USD
8/15/20252.43 USD
8/14/20252.51 USD
8/13/20252.63 USD
8/12/20252.56 USD
8/11/20252.64 USD
8/8/20252.32 USD
8/7/20252.26 USD
8/6/20252.09 USD
8/5/20252.05 USD
Access this data via the Eulerpool API
Get Free API Key

Cronos Group Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
87.24 M USD
-79.91 M USD
-73.96 M USD
Jan 1, 2024
117.62 M USD
-59.55 M USD
41.08 M USD
Jan 1, 2025
146.59 M USD
-14.62 M USD
-9.45 M USD
Jan 1, 2026 (e)
194.87 M USD
-136.18 M USD
34.79 M USD
Jan 1, 2027 (e)
220.35 M USD
-153.99 M USD
39.31 M USD
Jan 1, 2028 (e)
234.36 M USD
-163.78 M USD
47.58 M USD
Jan 1, 2029 (e)
197.11 M USD
-137.75 M USD
58.11 M USD
Jan 1, 2030 (e)
206.97 M USD
-144.64 M USD
64.66 M USD

Cronos Group Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 4, 2026, 3:58 PM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEB USD
NET INCOME GROWTH%
SHARESM
201520162017201820192020202120222023202420252026e2027e2028e2029e2030e
––3.0012.0023.0046.0074.0086.0087.00117.00146.00194.00220.00234.00197.00206.00
–––300.0091.67100.0060.8716.221.1634.4824.7932.8813.406.36-15.814.57
––-100.0050.00-73.91-54.35-22.9717.4412.6421.3742.4742.4742.4742.4742.4742.47
62.0062.00-3.006.00-17.00-25.00-17.0015.0011.0025.0062.0082.3893.4299.3783.6687.48
-1.00-3.00-10.00-21.00-115.00-169.00-196.00-104.00-79.00-59.00-14.00-136.00-153.00-163.00-137.00-144.00
––-333.33-175.00-500.00-367.39-264.86-120.93-90.80-50.43-9.59-70.10-69.55-69.66-69.54-69.90
–––-0.021.17-0.07-0.40-0.17-0.070.04-0.010.030.040.050.060.06
–––-2,200.00-5,652.38-106.26442.47-57.58-56.55-156.16-121.95-477.7814.7120.5123.4010.34
43.6978.25176.79172.27342.81351.58370.39376.96380.96385.56383.47383.47383.47383.47383.47383.47
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Cronos Group generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Cronos Group retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Cronos Group's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Cronos Group has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Cronos Group's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Cronos Group stock margins

The Cronos Group margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Cronos Group. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Cronos Group.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
-23.56 %
-264.55 %
-532.15 %
Jan 1, 2022
17.79 %
-120.34 %
-194.51 %
Jan 1, 2023
13.65 %
-91.60 %
-84.78 %
Jan 1, 2024
21.42 %
-50.63 %
34.93 %
Jan 1, 2025
42.81 %
-9.97 %
-6.44 %
Jan 1, 2026 (e)
42.81 %
-69.88 %
17.85 %
Jan 1, 2027 (e)
42.81 %
-69.88 %
17.84 %
Jan 1, 2028 (e)
42.81 %
-69.88 %
20.30 %

Cronos Group Stock Revenue, EBIT, Earnings per Share

The Cronos Group earnings per share therefore indicates how much revenue Cronos Group has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
0.20 USD
-0.53 USD
-1.07 USD
Jan 1, 2022
0.23 USD
-0.28 USD
-0.45 USD
Jan 1, 2023
0.23 USD
-0.21 USD
-0.19 USD
Jan 1, 2024
0.31 USD
-0.15 USD
0.11 USD
Jan 1, 2025
0.38 USD
-0.04 USD
-0.02 USD
Jan 1, 2026 (e)
0.51 USD
-0.36 USD
0.09 USD
Jan 1, 2027 (e)
0.57 USD
-0.40 USD
0.10 USD
Jan 1, 2028 (e)
0.61 USD
-0.43 USD
0.12 USD

Cronos Group business model & stock analysis

Cronos Group Inc is a Canadian company specializing in the production and distribution of medical and recreational cannabis. It was founded in 2013 and is headquartered in Toronto, Canada. Cronos Group Inc is one of the leading cannabis producers in Canada and has also made a name for itself in the international market. History Cronos Group Inc started as a medical cannabis startup focused on the cultivation and production of high-quality cannabis products for the medical market. In 2016, the company was listed on the Toronto Stock Exchange and raised 40 million Canadian dollars through a capital increase. In 2018, it received a $1.8 billion investment from Altria Group Inc, one of the world's largest tobacco companies. This investment helped Cronos grow and establish itself in the global cannabis market. Business model Cronos Group Inc has a diversified business model focusing on the production, processing, and marketing of cannabis products. The company specializes in the cultivation and production of high-quality cannabis products suitable for both the medical and recreational markets. Cronos Group Inc also produces cannabis oils, vaporizer pens, and other smoke-free products. The various subsidiaries Cronos Group Inc consists of several subsidiary companies focusing on different aspects of the cannabis industry. Some of the key subsidiaries of Cronos Group Inc are: 1. Peace Naturals - This company specializes in the cultivation of medical cannabis and also produces cannabis oils and vaporizable products. 2. Original BC - Original BC is a leading provider of recreational cannabis, offering a wide range of cannabis products. 3. Sublime Culture - Sublime Culture specializes in the production of cannabis extracts and the development of novel cannabis products like THC-infused gummy bears. Products Cronos Group Inc offers a wide range of cannabis products suitable for both the medical and recreational markets. Some of the key products of Cronos Group Inc include: 1. Cannabis oils - The company produces a wide range of cannabis oils suitable for medical and recreational use. 2. Vaporizer pens - Cronos Group Inc also produces vaporizable products for smoke-free consumption of cannabis products. 3. Edibles - The company also offers a range of novel cannabis products like THC-infused gummy bears, contributing to the growth of the market. Conclusion Cronos Group Inc is one of the leading cannabis companies worldwide specializing in the production and distribution of medical and recreational cannabis. The company has made a name for itself with its wide range of cannabis products and has grown and established itself in the international market through the investment from Altria Group Inc. Cronos Group Inc has implemented a diversified business model, offering medical cannabis, recreational cannabis, and novel cannabis products to grow in the increasing demand and provide its customers with a wide range of offerings.

Cronos Group SWOT Analysis

Strengths

1. Strong brand reputation and market presence: Cronos Group Inc has established itself as a leading player in the cannabis industry, both in Canada and globally.

2. Solid financial position: The company has sufficient financial resources, enabling it to invest in research and development, expand production capacities, and pursue strategic partnerships.

3. Diverse product portfolio: Cronos Group offers a wide range of cannabis products, including dried flower, oils, and vaporizers, catering to different consumer preferences and market segments.

Weaknesses

1. Regulatory challenges: The cannabis industry operates under strict regulations, which may result in uncertainties and constraints for Cronos Group, especially in international markets.

2. Limited production capacity: Despite ongoing expansions, the company's production capacity may not be sufficient to meet the growing demand for cannabis products, potentially hindering market share growth.

3. Higher product prices: Cronos Group's premium positioning and focus on quality may result in comparatively higher prices, making its products less affordable for price-sensitive consumers.

Opportunities

1. Legalization and market expansion: Increasing legalization of cannabis across different jurisdictions presents opportunities for Cronos Group to penetrate new markets and drive sales growth.

2. Expansion of product offerings: The company can diversify its product portfolio further by introducing innovative cannabis-based products, such as edibles, beverages, and cosmetics, to tap into evolving consumer trends.

3. Strategic partnerships: Collaborating with established companies in related industries, such as pharmaceuticals or consumer goods, can provide Cronos Group with access to new distribution channels and enhance market reach.

Threats

1. Competitive market landscape: The cannabis industry is becoming increasingly competitive, with the presence of both established players and new entrants, posing challenges for Cronos Group to maintain its market share and pricing power.

2. Legal and regulatory risks: Changes in laws and regulations, both domestically and internationally, regarding the production, distribution, or use of cannabis can impact the company's operations and profitability.

3. Negative social perception: Despite ongoing efforts to normalize the use of cannabis, societal stigma surrounding marijuana consumption may hinder widespread acceptance and limit the market potential for Cronos Group's products.

Cronos Group Segments

Cronos Group Revenue by Segment

  • 3 Years

  • 5 Years

  • Max

Cannabis flower
Cannabis extracts
Other
Details
Date
Cannabis flower
Cannabis extracts
Other
Jan 1, 2020
27.93 M USD
18.25 M USD
533,000.00 USD
Jan 1, 2021
55.19 M USD
18.68 M USD
560,000.00 USD
Jan 1, 2022
63.59 M USD
27.68 M USD
634,000.00 USD
Jan 1, 2023
62.07 M USD
24.57 M USD
602,000.00 USD
Jan 1, 2024
87.91 M USD
29.17 M USD
535,000.00 USD
Jan 1, 2025
108.48 M USD
37.70 M USD
411,000.00 USD

Cronos Group Revenue by Region

  • 3 Years

  • 5 Years

  • Max

Canada
Israel
Other countries
United States
Details
Date
Canada
Israel
Other countries
United States
Jan 1, 2020
34.54 M USD
0.00 USD
2.69 M USD
9.50 M USD
Jan 1, 2021
50.29 M USD
13.38 M USD
891,000.00 USD
9.87 M USD
Jan 1, 2022
56.23 M USD
30.52 M USD
0.00 USD
5.16 M USD
Jan 1, 2023
64.70 M USD
21.13 M USD
1.41 M USD
0.00 USD
Jan 1, 2024
82.44 M USD
28.37 M USD
6.81 M USD
0.00 USD
Jan 1, 2025
90.33 M USD
41.80 M USD
14.46 M USD
0.00 USD

Cronos Group Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Cronos Group historical P/E ratio, EBIT multiple, and P/S ratio

Cronos Group annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Cronos Group shares outstanding

The number of shares of Cronos Group was 383.47 M in 2025. This indicates how many shares Cronos Group is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
370.39 M Stocks
Jan 1, 2022
376.96 M Stocks
Jan 1, 2023
380.96 M Stocks
Jan 1, 2024
385.56 M Stocks
Jan 1, 2025
383.47 M Stocks
Jan 1, 2026 (e)
383.47 M Stocks
Jan 1, 2027 (e)
383.47 M Stocks
Jan 1, 2028 (e)
383.47 M Stocks

Cronos Group stock splits

In Cronos Group's history, there have been no stock splits.

Current Cronos Group forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
88.89 % (8)
Hold
11.11 % (1)
Sell
0.00 % (0)
12M Price Target
0.00
Last Price
2.74
Currency
USD
12M Return Potential
-100.00 %
LTM Return
0 %

Cronos Group Analyst Rating Actions

DateFirmActionRatingReliability
5/15/2024
CIBC
CIBC
MaintainedOutperform–
4/8/2024
B of A Securities
B of A Securities
MaintainedUnderperform70
12/28/2023
B of A Securities
B of A Securities
MaintainedUnderperform70
5/15/2023
Barclays
Barclays
MaintainedEqual Weight33
11/2/2022
Bernstein
Bernstein
MaintainedMarket PerformPerform–
9/30/2022
Barclays
Barclays
MaintainedEqual Weight33
3/22/2022
Barclays
Barclays
UpgradeUnderweightEqual Weight33
3/7/2022
Piper Sandler
Piper Sandler
MaintainedNeutral51
2/22/2022
Piper Sandler
Piper Sandler
MaintainedNeutral51
2/22/2022
Canaccord Genuity
Canaccord Genuity
MaintainedSell59

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

Cronos Group Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
5/7/20240.01USD-26.05 MUSD-2024 Q1
2/26/2024-0.02USD-25.79 MUSD-2023 Q4
8/7/2023-0.05USD-28.82 MUSD-2023 Q2
5/8/2023-0.05USD-27.30 MUSD-2023 Q1
2/27/2023-0.05USD-24.64 MUSD-2022 Q4
11/7/2022-0.06USD-25.30 MUSD-2022 Q3
8/9/2022-0.06USD-28.41 MUSD-2022 Q2
5/10/2022-0.07USD-24.21 MUSD-2022 Q1
3/1/2022-0.13USD-24.45 MUSD-2021 Q4
2/18/2022-0.10USD-18.88 MUSD-2021 Q3

EESG©

Eulerpool ESG Scorecard© for the Cronos Group stock

30/100
7
Environment
53
Social
30
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Cronos Group shareholder structure

% Name
3.39433%
Gorenstein (Michael Ryan)
Gorenstein (Michael Ryan)
2.07129%
Chescapmanager, L.L.C.
Chescapmanager, L.L.C.
1.78879%
D. E. Shaw & Co., L.P.
D. E. Shaw & Co., L.P.
1.08040%
Tidal Investments LLC
Tidal Investments LLC
0.72002%
MMCAP Asset Management
MMCAP Asset Management
0.65356%
Dimensional Fund Advisors, L.P.
Dimensional Fund Advisors, L.P.
...

Cronos Group Beneficial Ownership Filings (SEC 13D/G)

Free Float
51.4%
Float Shares
-
Shares Outstanding
-

Cronos Group Executives and Management Board

14 members · avg. age 47 · 21 % women

MG

Mr. Michael Gorenstein (38)

Executive Chairman of the Board, President, Chief Executive Officer · since 2016

4.15 M USD

Management

JJ

Mr. Jeffrey Jacobson (39)

Chief Growth Officer

1.12 M USD
AS

Ms. Anna Shlimak (39)

Chief Financial Officer, Senior Vice President

836,509.00 USD
SB

Ms. Shannon Buggy (55)

Senior Vice President, Global Head of People

760,580.00 USD
AW

Mr. Adam Wagner (42)

Senior Vice President, Head of Cronos Israel

–
AW

Mr. Arye Weigensberg (42)

Senior Vice President, Head of Research & Development

–
JK

Mr. Jared Kenost

Principal Accounting Officer, Vice President, Controller

–

Board of Directors

JR

Mr. James Rudyk (58)

Lead Independent Director

245,000.00 USD
JA

Mr. Jason Adler (53)

Independent Director

215,000.00 USD
MG

Mr. Murray Garnick (65)

Independent Director

175,000.00 USD
KK

Mr. Kamran Khan (51)

Independent Director

–
DM

Mr. Dominik Meier (47)

Independent Director

–
ES

Ms. Elizabeth Seegar (47)

Independent Director

–

Cronos Group Supply Chain

Cronos Group Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
4 companies
#Nameβ 1YTrend
1
MediPharm Labs
Supplier·Pharmaceuticals·CA
0.08
-0.53
0.59
0.68
0.97
0.47
—
#Nameβ 1YTrend
1
urban-gro
Supplier·Machinery·US
-0.16
-0.46
0.56
0.55
0.41
—
—
2
Altria Group
Supplier·Customer·Tobacco·US
0.08
0.22
-0.42
-0.80
-0.41
-0.42
-0.15
3
LVMH Moet Hennessy Louis Vuitton
Customer·Textiles, Apparel & Luxury Goods·FR
0.25
-0.45
-0.44
0.40
-0.02
-0.32
-0.01

Frequently asked questions about Cronos Group

The business model of Cronos Group Inc. revolves around the cultivation, production, and distribution of cannabis and cannabis-derived products worldwide. As a leader in the cannabis industry, Cronos Group focuses on developing and building iconic brands, partnering with retail networks, and expanding distribution channels. By prioritizing innovation and research, Cronos Group aims to provide high-quality and differentiated cannabis products to its diverse customer base. With a strategic global presence and a commitment to sustainability, Cronos Group Inc. strives to drive industry growth and shape the future of cannabis.

Cronos Group Inc is primarily active in the cannabis industry.

The main competitors of Cronos Group Inc in the market are Canopy Growth Corporation, Aurora Cannabis Inc, and Tilray Inc.

Cronos Group Inc, a leading Canadian cannabis company, has a rich history and background. Founded in 2013, it quickly established itself as a pioneer in the cannabis industry. The company operates globally and focuses on developing and distributing high-quality cannabis products. Cronos Group Inc has successfully formed partnerships with renowned brands, such as Marlboro-maker Altria Group, enhancing its market position. With a commitment to innovation and sustainability, Cronos prides itself on its diverse portfolio of brands and a strong research and development team. As a market leader, Cronos Group Inc continues to shape the future of the cannabis industry with its dedication to excellence and commitment to delivering shareholder value.

Cronos Group Inc has achieved several significant milestones. The company became the first cannabis producer to be listed on a major stock exchange in 2018, trading on the NASDAQ under the ticker symbol CRON. Additionally, Cronos Group Inc expanded its global presence by entering strategic partnerships and acquisitions in various countries. These include a joint venture in Israel, a supply and distribution agreement in Germany, and a partnership in Australia. Furthermore, the company has focused on research and development initiatives to innovate and develop novel cannabinoid-based products. Cronos Group Inc continues to make strides in the cannabis industry, positioning itself for further growth and success.

Cronos Group Inc is primarily present in Canada and the United States.

Cronos Group Inc represents core values of integrity, innovation, and responsibility. As a leading global cannabinoid company, Cronos Group is committed to providing innovative and high-quality products to its customers. The company's corporate philosophy revolves around transparency, sustainability, and community partnerships. Cronos Group focuses on advancing cannabinoid research, developing industry-leading intellectual property, and driving the growth of the cannabis industry. With a commitment to regulatory compliance and ethical practices, Cronos Group Inc prioritizes the well-being and satisfaction of their stakeholders while promoting the benefits of cannabinoid-based therapies.

Analysts currently set an average price target of 3.37 USD for the Cronos Group stock (median: 3.37 USD), implying +22.9 % versus the latest price. The consensus is based on 8 analyst ratings.

Cronos Group Analyst Price Targets 2026

9 analysts currently rate the Cronos Group stock: 8 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Cronos Group to generate revenue of 194.87 M USD and earnings per share of 0.09 USD.

Cronos Group Analyst Price Targets 2026

Converted at the current exchange rate, the Cronos Group share trades at 2.38 EUR (2.74 USD).

The Cronos Group share (CRON.TO) is listed on 5 stock exchanges, including: NASDAQ (CRON), Frankfurt (7CI.F), München (7CI.MU), Düsseldorf (7CI.DU), Toronto (CRON.TO).

The Cronos Group Inc is a Canadian company that operates in the manufacturing and marketing of cannabis products. Cronos' business model is based on vertical integration, allowing the company to complete all steps from cultivation to sales under one roof. One of Cronos' core divisions is cannabis cultivation. The company operates its own cultivation areas in Canada and other countries, equipped with the latest technology and highest standards. Through outdoor and indoor cultivation, Cronos can offer a wide range of cannabis varieties that cater to individual customer needs. Another important aspect of Cronos is the production of cannabis extracts and derivatives. The company utilizes its own cultivation areas and processes the harvested material into high-quality products such as oils, tinctures, capsules, and vapes. The broad portfolio of cannabis derivatives allows Cronos to target different market segments and cover a wide range of applications. In addition to production, Cronos also offers comprehensive consulting services. Experienced consultants and experts are available to assist customers in selecting the right product and individual dosage. This builds trust and customer satisfaction and strengthens the company's image as a responsible cannabis provider. Cronos markets its products through various channels, including its own online shop, retailers, and wholesalers. The company has been particularly successful in international marketing. Cronos collaborates with partners in different countries to position its products in the global market. The company focuses on a high-quality brand strategy and clear positioning as a premium provider. In addition to the mentioned business areas, Cronos also invests in research and development. This is aimed at strengthening the company's position as an innovation leader in the cannabis industry and exploring new applications. One focus is on the medical use of cannabis derivatives, which have shown positive effects in numerous medical conditions. Overall, Cronos' business model is characterized by a clear strategy, professional management, and a broad portfolio of high-quality products. Successful international marketing and positioning as a premium provider contribute significantly to the company's success. Investments in research and development will continue to support Cronos in offering innovative products and expanding its market position.

The expected revenue of Cronos Group is 194.87 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Cronos Group is 34.79 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Cronos Group is currently 30.20. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Cronos Group stock.

The price-to-sales ratio (P/S) of Cronos Group is currently 5.39. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Cronos Group stock.

The Eulerpool Quality Score for Cronos Group is 3/10.

The ISIN of Cronos Group is CA22717L1013. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Cronos Group is A2DMQY. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Cronos Group is CRON.TO. The ticker symbol is used to trade Cronos Group shares on the stock exchange.

Cronos Group paid dividends every year for the past 0 years.

Cronos Group is assigned to the 'Health' sector.

The dividends of Cronos Group are distributed in USD.

All fundamentals and in-depth analysis of Cronos Group

Our stock analysis for Cronos Group stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cronos Group. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Cronos Group Stock
Cronos Group Revenue→
Cronos Group Stock
Cronos Group Net Income→
Cronos Group Stock
Cronos Group P/E→
Cronos Group Stock
Cronos Group P/S→
Cronos Group Stock
Cronos Group EBIT→
Cronos Group Stock
Cronos Group Dividend→
Cronos Group Stock
Cronos Group Directors Dealings→
Cronos Group Stock
Cronos Group Stocks→
Cronos Group Stock
Cronos Group Market capitalization→
Cronos Group Stock
Cronos Group Debt→
Cronos Group Stock
Cronos Group Liabilities→
Cronos Group Stock
Cronos Group Equity→
Cronos Group Stock
Cronos Group AAQS→
Cronos Group Stock
Cronos Group Employees→
Cronos Group Stock
Cronos Group ROE→
Cronos Group Stock
Cronos Group ROA→
Cronos Group Stock
Cronos Group ROCE→
Cronos Group Stock
Cronos Group News→
Cronos Group Stock
Cronos Group Analyst Price Targets→